Patents by Inventor Jasbir Seehra

Jasbir Seehra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Truncated ACTRIIB-FC fusion protein
    Patent number: 9181533
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: November 10, 2015
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, Ravindra Kumar
  • Isolated polynucleotide that encodes an ActRIIa-Fc fusion polypeptide
    Patent number: 9163075
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: October 20, 2015
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • BMP-ALK3 ANTAGONISTS AND USES FOR PROMOTING BONE GROWTH
    Publication number: 20150266941
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density and strength. In certain embodiments, the present invention provides ALK3 polypeptides, including ALK3-Fc fusion proteins.
    Type: Application
    Filed: February 2, 2015
    Publication date: September 24, 2015
    Inventor: Jasbir Seehra
  • ACTRIIB-FC polynucleotides, polypeptides, and compositions
    Patent number: 9138459
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: September 22, 2015
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE
    Publication number: 20150183849
    Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
    Type: Application
    Filed: November 7, 2014
    Publication date: July 2, 2015
    Inventors: JASBIR SEEHRA, JOHN KNOPF, RAVINDRA KUMAR, ERIK VOGAN
  • ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20150183845
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: November 20, 2014
    Publication date: July 2, 2015
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • Cerberus/Coco derivatives and uses thereof
    Patent number: 9045553
    Abstract: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: June 2, 2015
    Assignee: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra
  • METHODS FOR INCREASING ADIPONECTIN
    Publication number: 20150056200
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.
    Type: Application
    Filed: June 30, 2014
    Publication date: February 26, 2015
    Inventors: Jasbir Seehra, Ravindra Kumar, Jennifer Lachey, Alan Koncarevic
  • Polynucleotides encoding BMP-ALK3 antagonists
    Patent number: 8945877
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density and strength. In certain embodiments, the present invention provides ALK3 polypeptides, including ALK3-Fc fusion proteins.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: February 3, 2015
    Assignee: Acceleron Pharma, Inc.
    Inventor: Jasbir Seehra
  • ACTRIIB PROTEINS AND VARIANTS AND USES THEREFORE RELATING TO UTROPHIN INDUCTION FOR MUSCULAR DYSTROPHY THERAPY
    Publication number: 20150023970
    Abstract: In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand.
    Type: Application
    Filed: April 16, 2014
    Publication date: January 22, 2015
    Applicant: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Jennifer Lachey
  • COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE
    Publication number: 20150010555
    Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
    Type: Application
    Filed: April 24, 2014
    Publication date: January 8, 2015
    Applicant: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Ravindra Kumar
  • Antagonists of activin-actriia and uses for increasing red blood cell levels
    Patent number: 8895016
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: November 25, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • Compositions and methods for increasing serum half-life
    Patent number: 8883982
    Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 11, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Ravindra Kumar, Erik Vogan
  • METHODS FOR INCREASING THERMOGENIC ADIPOCYTES
    Publication number: 20140328845
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Noda1, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Application
    Filed: April 1, 2014
    Publication date: November 6, 2014
    Applicant: ACCELERON PHARMA INC.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • ISOLATED NUCLEOTIDE SEQUENCES ENCODING GDF TRAPS
    Publication number: 20140314759
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: March 7, 2014
    Publication date: October 23, 2014
    Applicant: ACCELERON PHARMA, INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • ANTAGONISTS OF BMP9, BMP10, ALK1 AND OTHER ALK1 LIGANDS, AND USES THEREOF
    Publication number: 20140227254
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
    Type: Application
    Filed: December 27, 2013
    Publication date: August 14, 2014
    Applicant: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Robert S. Pearsall, Asya Grinberg, Ravindra Kumar
  • Uses of Cerberus and derivatives thereof
    Patent number: 8796199
    Abstract: The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: August 5, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, John Knopf, Ravindra Kumar, Jasbir Seehra
  • METHODS OF PROMOTING FAT LOSS COMPRISING ADMINISTERING AN ALK7 INHIBITOR
    Publication number: 20140205600
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Application
    Filed: January 24, 2014
    Publication date: July 24, 2014
    Applicant: ACCELERON PHARMA INC.
    Inventors: John Knopf, Jasbir Seehra
  • ACTRIIA BINDING AGENTS AND USES THEREOF
    Publication number: 20140199317
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIA and uses for same.
    Type: Application
    Filed: January 24, 2014
    Publication date: July 17, 2014
    Applicant: ACCELERON PHARMA, INC.
    Inventors: Jasbir Seehra, Erik Martinez-Hackert
  • BMP10 propeptides and related methods
    Patent number: 8772234
    Abstract: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: July 8, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf